Immunotherapy series | Selecting between first-line therapies in stage IV NSCLC

Oncology Knowledge into Practice Podcast

Several immune checkpoint inhibitors have indications in non small-cell lung cancer (NSCLC), but it is not always easy to decide which patients to treat when, and with which regimen. In today’s episode, we’ve invited Professor Martin Reck from the Lung Clinic Grosshansdorf in Germany to answer some of our questions about best practice when considering immune checkpoint inhibitors for patients with NSCLC.

References:

Postmus PE, et al. Annals of Oncology. 2017; 28: iv1-iv21

Socinski MA et al. JCO. 2019; 37(15_suppl): 9012-9012

Pacheco JM. Translational Lung Cancer Research. 2019; 8(5): 723-727

Funazo T et al. J Thorac Oncol. 2017; 12(9): e140-e141

Sridhar S et al. Clin Lung Cancer. 2019; 20(6): e601-e608

Chai Q-Q et al. Frontiers in Pharmacology. 2019; 10:1260

Peng M et al. OncoTargets and Therapy. 2018; 11: 7369-7383

Gadgeel S et al. JCO. 2020; 38(14): 1505-1517

Ettinger DS et al. J Natl Compr Canc Netw. 2017; 15(4): 504-535

Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.

This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.